APOE and Alzheimer disease: Postmortem AD brains from APOE*ε2 carriers have lower densities of Aβ containing neuritic plaques than those from APOE*ε3/3 individuals [7–9], suggesting a slower antemortem Aβ deposition in APOE*ε2 carriers.